Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Silvia Garattini"'
Autor:
Raffaella Marocco, Cosmo Del Borgo, Eeva Tortellini, Silvia Garattini, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Mariasilvia Guardiani, Paola Zuccalà, Danilo Alunni Fegatelli, Alessandra Spagnoli, Miriam Lichtner, LATINA COVID-group
Publikováno v:
Viruses, Vol 15, Iss 4, p 947 (2023)
In this retrospective comparative study, we evaluated the effectiveness of remdesivir (RDSV) in patients with SARS-CoV-2 pneumonia. Individuals hospitalized between March 2020 and August 2022 at S.M. Goretti Hospital, Latina, with a positive test for
Externí odkaz:
https://doaj.org/article/763f32d87fdb4c6d8af405374cdb09e8
Autor:
Cosmo Del Borgo, Silvia Garattini, Carolina Bortignon, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Sara Giovanna De Maria, Sara Corazza, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Margherita De Masi, Ombretta D’Onofrio, Gabriele Bagaglini, Gabriella Bonanni, Paola Zuccalà, Paolo Fabietti, Eeva Tortellini, Mariasilvia Guardiani, Alessandra Spagnoli, Raffaella Marocco, Danilo Alunni Fegatelli, Miriam Lichtner, LATINA COVID-group
Publikováno v:
Viruses, Vol 15, Iss 4, p 1025 (2023)
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability i
Externí odkaz:
https://doaj.org/article/fe1ba87f66064f51bb313b9b2009f9e4
Autor:
COVID-group, Cosmo Del Borgo, Silvia Garattini, Carolina Bortignon, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Sara Giovanna De Maria, Sara Corazza, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Margherita De Masi, Ombretta D’Onofrio, Gabriele Bagaglini, Gabriella Bonanni, Paola Zuccalà, Paolo Fabietti, Eeva Tortellini, Mariasilvia Guardiani, Alessandra Spagnoli, Raffaella Marocco, Danilo Alunni Fegatelli, Miriam Lichtner, LATINA COVID-group LATINA
Publikováno v:
Viruses; Volume 15; Issue 4; Pages: 1025
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability i
Autor:
COVID-group, Raffaella Marocco, Cosmo Del Borgo, Eeva Tortellini, Silvia Garattini, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Mariasilvia Guardiani, Paola Zuccalà, Danilo Alunni Fegatelli, Alessandra Spagnoli, Miriam Lichtner, LATINA COVID-group LATINA
Publikováno v:
Viruses; Volume 15; Issue 4; Pages: 947
In this retrospective comparative study, we evaluated the effectiveness of remdesivir (RDSV) in patients with SARS-CoV-2 pneumonia. Individuals hospitalized between March 2020 and August 2022 at S.M. Goretti Hospital, Latina, with a positive test for
Autor:
Maria Antonella Zingaropoli, Alberico Parente, Blerta Kertusha, Roberta Campagna, Tiziana Tieghi, Silvia Garattini, Raffaella Marocco, Anna Carraro, Eeva Tortellini, Mariasilvia Guardiani, Federica Dominelli, Ombretta Turriziani, Maria Rosa Ciardi, Claudio Maria Mastroianni, Cosmo Del Borgo, Miriam Lichtner
Publikováno v:
Open Forum Infectious Diseases. 9
In a male with severe proctitis, monkeypox virus DNA was detected in skin lesions, blood, the nasopharynx, and the rectum, underlying generalized viral spreading. Rectal involvement was still found when skin lesions disappeared. At this early stage,
Autor:
Anna Carraro, Valeria Belvisi, Silvia Garattini, Simone Cacace, Raffaella Marocco, Cosmo Del Borgo, Francesco Fiorentino, Salvatore Perrone, Giuseppe Cimino, Miriam Lichtner
Publikováno v:
AIDS (London, England). 36(13)